Shilpa Medicare Ltd Q3 FY2026 Concall Summary

Key Takeaways

• Record quarter, operating leverage kicking in: Highest-ever quarterly revenue and EBITDA, with EBITDA margin expanding from 26% to 28%, as the company shifts from investment mode to sweating assets.
• NorUDCA launch exceeded expectations: Growth previously guided for Q1 FY27 is now being pulled forward into Q4 FY26 itself, backed by a strong order book.
• The pipeline is dense with near-term catalysts: A PDUFA date, an EMA-approved patch, multiple Phase III readouts, and an ADC facility commissioning are all stacked in the next two to four quarters.
• Management is drawing a line under the investment cycle: Explicit commitment to avoid new long-gestating investments; focus is now on execution, scaling, and maximizing ROCE from assets already built.
• What to watch next quarter: Whether the NorUDCA order book converts into sustained revenue, the U.S. FDA's response to the Jadcherla CAPA submission, and any partnership announcements for the biologics platform.

NorUDCA: The Near-Term Growth Engine

• Launch beat plan: The domestic launch, executed through a dual strategy of own-label plus partnerships with three large pharma companies, exceeded internal expectations. Strong physician reception has already translated into a healthy order book.
• Pull-forward effect: Management had previously guided for growth contribution to begin in Q1 FY27. That growth is now expected to materialize in Q4 FY26 itself, implying a material step-up in the current quarter.
• Global ambitions: The company plans to take NorUDCA to Europe and the U.S., with human studies for Europe targeted to start in the next financial year. Additional indications for the same molecule are also under development.
• Guidance posture: Management declined to quantify the opportunity size in this call but indicated it will be in a position to guide on it in upcoming quarters.

Keshav Bhutada: "See, especially on NorUDCA, the launch was very successful, and it has exceeded our expectations. So whatever growth we were expecting to start from Q1, we would see that in Q4FY26 itself."

Pipeline Catalysts: A Crowded Next 12 Months

• Unicycive NCE (Oxylanthanum Carbonate): Partner resubmitted the filing to the U.S. FDA and received a PDUFA date of June 29, 2026. Shilpa's dedicated commercial block is likely to be commissioned in Q4 FY26, with exhibit batches in Q1 FY27. Commercialization is expected in FY27.
• Rotigotine transdermal patch: Received EMA marketing authorization; launch preparations are underway with a market partner, planned for FY27. A U.S. filing is targeted for Q4 FY26.
• Ondansetron long-acting injection: Phase III studies completed successfully in India; commercialization planned for H1 FY27. European Phase III studies are set to begin in Q4 FY26 and complete in FY27.
• Aflibercept biosimilar: Phase III studies in India progressing as planned; submission targeted for H1 FY27. Management expects this to remain a limited-competition opportunity in India.
• ADC manufacturing facility: First-of-its-kind integrated ADC facility in India (payload, linker, conjugation) planned for commissioning in Q4 FY26. The first ADC product (SBPL01) will enter human studies in FY27.
• Albumin: Global clinical trial protocol approval received. IMPD submission for Europe is targeted for Q4 FY26; India study completion is expected by end-FY27 or early FY28, with India commercialization possible in FY28.
• Semaglutide: API validation batches ongoing; both injectable and oral solid formulation development completed. Registration batches planned for H1 FY27, to be filed globally. Large-scale peptide manufacturing capacity capex targeted for completion in H2 FY27.

Base Business: Formulation Surge, API Goes Captive

• Formulation ex-licensing: The base business grew 104% QoQ and 83% for the nine-month period. EU Formulation revenue grew over 100% YoY. Management indicated that INR150-plus crores in quarterly formulation base revenue is a reasonable assumption for upcoming quarters.
• API segment: Non-captive API revenue was flat (₹186 cr vs ₹183 cr), but the strategic shift is deliberate: the API unit is progressively supporting the in-house formulation portfolio. Including captive consumption, API grew 11%.
• Oncology scale-up: A large part of oncology API supplies now goes toward captive formulation sales. Three new oncology products were validated in the quarter, and 10 new products were added to the development grid. Management expects a wave of filings over the next year, with 4-5 products in advanced stages.
• RoW business: Tender-driven and lumpy by nature; quarter-on-quarter variation is normal as some tenders cover two quarters. On a year-on-year basis, the business has grown.
• Licensing income: Declined in the quarter, but management characterized this as normal variation tied to product, market, and milestone realization timing.

CDMO & NCE: The Differentiated Moat

• First NCE commercialized: The first NCE program with a U.S. customer has now been commercialized by the partner, marking a milestone in Shilpa's CDMO evolution.
• Second NCE in Phase III: Studies are ongoing for the second U.S. NCE program.
• Phase II NCE: A program where Shilpa is developing both API and formulation for the innovator received orphan drug and Fast Track designations, with applications in multiple indications.
• Specialty CDMO additions: Three new CDMO programs were added in the quarter.
• mAbTree product: Shilpa is the exclusive CDMO partner for a product that received orphan drug designation for two separate indications.
• Biologics CDMO: Two partner programs are expected to enter Phase I studies in the next financial year. Management expects to secure additional partnerships in FY27.

Keshav Bhutada: "Our model is simple: invest in R&D, build differentiated assets, launch it with strong margins, scale it through partnership."

Financial Health & Capital Allocation

• Profitability inflection: Nine-month PAT is nearly double the full-year PAT of FY25. Adjusted ROCE improved from 3.5% in FY23 to over 17% in the first nine months, excluding investments in high-growth businesses like Biologics and NBE.
• Debt trajectory: Debt-to-equity is comfortable at approximately 0.25-0.26x, and the debt-to-EBITDA ratio is steadily declining. Management does not intend to increase borrowing; debt will keep reducing through term loan repayments, though commercial borrowing may be considered opportunistically.
• Investment cycle closed: Management stated unequivocally that the heavy-lifting investment phase is largely complete. The company will not invest in anything that is long-gestating. The focus is now on sweating existing assets for maximum returns.
• Capacity headroom: A new oral solid dosage line has been commissioned and will contribute revenue in FY27. Non-oncology formulation capacity is not yet fully utilized, with revenues expected to ramp quarter-on-quarter.

Keshav Bhutada: "Whatever heavy lifting was required for the company on the investment side, we have largely completed in last many years, and the focus now is on execution, scaling and getting maximum ROCE from all our investments."

Regulatory & Competitive Positioning

• Jadcherla U.S. FDA warning letter: All CAPA activities have been completed and responses submitted to the U.S. FDA. The company is now waiting for the agency's revert.
• Non-infringing oncology API: Scale-up of one non-infringing oncology API has been completed; validation batches are planned for Q4 FY26, with a formulation also planned for the same product.
• Differentiation thesis: Management anchored its competitive strategy in having something differentiated, either in API or formulation, that helps secure better market share. The non-infringing process portfolio and complex product pipeline (patches, long-acting injectables, ADCs) are the tangible expression of this.

Keshav Bhutada: "And one differentiation which Shilpa will always have, I feel, is, we'll have something differentiated, either in API or in Formulation, which will help us in getting better market share."

Guidance & Commitments

Key Metrics